JAK Mutations As Escape Mechanisms to Anti-PD-1 Therapy

Overview

Journal Cancer Discov

Specialty Oncology

Date 2017 Feb 8

PMID 28167612

Citations 18

Authors

Aurelien Marabelle

Sandrine Aspeslagh

Sophie Postel-Vinay

Jean-Charles Soria

Affiliations

Soon will be listed here.

Abstract

JAK mutations could be one of the primary escape mechanisms to anti-PD-1/PD-L1 immunotherapy via impaired IFNγ signaling in cancer cells and could be used to identify patients unlikely to benefit from these treatments. Cancer Discov; 7(2); 128-30. ©2017 AACR.See related article by Shin et al., p. 188.

Citing Articles

Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.

Cesano A, Augustin R, Barrea L, Bedognetti D, Bruno T, Carturan A J Immunother Cancer. 2025; 13(1).

PMID: 39824527 PMC: 11749597. DOI: 10.1136/jitc-2024-008876.

Tumour mutational burden: clinical utility, challenges and emerging improvements.

Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altburger C Nat Rev Clin Oncol. 2024; 21(10):725-742.

PMID: 39192001 DOI: 10.1038/s41571-024-00932-9.

PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications.

Ortega M, Boaru D, De Leon-Oliva D, Fraile-Martinez O, Garcia-Montero C, Rios L J Mol Med (Berl). 2024; 102(8):987-1000.

PMID: 38935130 DOI: 10.1007/s00109-024-02463-3.

Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation, mutation, and high microsatellite instability.

Yang M, Yu P, He Z, Deng J Front Immunol. 2024; 14:1266304.

PMID: 38332908 PMC: 10850318. DOI: 10.3389/fimmu.2023.1266304.

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.

Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q Signal Transduct Target Ther. 2023; 8(1):204.

PMID: 37208335 PMC: 10196327. DOI: 10.1038/s41392-023-01468-7.